论文部分内容阅读
本文报告肺癌病人肿瘤标记物组织多肽抗原(TPA)的临床意义。以原发性肺癌病人198例和转移性肺癌14例为研究对象。以医院健康职工88名,肺部炎症性疾患133例和肺部良性肿瘤25例为对照组。原发性肺癌的组织类型为腺癌117例、鳞癌59例、小细胞癌15例、大细胞癌7例。按 TNM 分期,Ⅰ期38例、Ⅱ期3例、Ⅲ期65例、Ⅳ期92例。恶性胸水36例,良性胸水13例。以血清 TPA 超过110U/L 为阳性。结果:198例肺癌中各肿瘤标记的阳性率,TPA为62.6%、癌胚.抗原(CEA)为73.7%、铁蛋白46%。133例炎症性肺疾患中假阳性率,TPA 为31.6%、CEA 40.6%、铁蛋白23.8%。准确率(肺癌阳性病
This paper reports the clinical significance of tissue polypeptide antigen (TPA) in tumor markers of lung cancer patients. 198 cases of primary lung cancer and 14 cases of metastatic lung cancer were studied. Eighty-eight hospital health workers, 133 pulmonary inflammatory diseases and 25 benign lung tumors were used as control groups. The primary lung cancer tissue types are 117 cases of adenocarcinoma, 59 cases of squamous cell carcinoma, 15 cases of small cell carcinoma, and 7 cases of large cell carcinoma. According to the TNM stage, there were 38 cases of stage I, 3 cases of stage II, 65 cases of stage III, and 92 cases of stage IV. There were 36 cases of malignant pleural effusion and 13 cases of benign pleural effusion. Serum TPA was more than 110 U/L positive. RESULTS: The positive rate of each tumor marker in 198 lung cancer patients was 62.6% for TPA, 73.7% for carcinoembryonic antigen (CEA), and 46% for ferritin. The false positive rate in 133 cases of inflammatory lung diseases was 31.6% for TPA, 40.6% for CEA, and 23.8% for ferritin. Accuracy (lung cancer positive disease)